The New Number That Changes the Conversation

Eli Lilly's retatrutide posted 28% average body weight loss across participants in an 80-week clinical study, according to reporting by The New York Times.

That's the average. Not the top performers. Not early responders. Everyone.

For context: Wegovy (semaglutide at 2.4 mg) delivers roughly 15% average weight loss. Retatrutide hit 28% across the board.

This represents a different category of drug.

What Is Retatrutide, Exactly?

Retatrutide is a triple-hormone agonist — it targets GLP-1, GIP, and glucagon receptors simultaneously. Wegovy and Ozempic hit one receptor. Mounjaro and Zepbound hit two. Retatrutide hits three.

More receptor targets means more metabolic levers being pulled at once. The 28% figure, reported by the NYT based on Eli Lilly's own data release, reflects that multi-pronged mechanism working in practice.

Bloomberg confirmed the study framing as a "record weight loss" result, though their full coverage was behind a paywall. The directional confirmation from two independent newsrooms is still meaningful.

The Age Gap Nobody's Talking About

Separate from the retatrutide news, a major new analysis published May 11, 2026 through the European Association for the Study of Obesity confirmed that semaglutide works just as well in adults over 65 as it does in younger populations.

The analysis, led by Prof. Luca Busetto of the University of Padova in Italy, pulled data from STEP trials 1, 3, 4, 5, 8, and 9. Older adults with obesity (BMI ≥30, or ≥27 with a related complication, no diabetes) lost over 15% of their body weight on average over 68 weeks, according to ScienceDaily.

Many moved out of obesity BMI categories entirely. Cardiometabolic markers — blood pressure, cholesterol, blood glucose, inflammatory markers — all improved.

Older adults are often excluded from the marketing narrative around GLP-1 drugs. Doctors have been cautious about prescribing to patients over 65 due to concerns about muscle loss, frailty, and compounding health conditions. This data directly challenges that hesitancy.

Novo Nordisk co-funded this research. That doesn't automatically invalidate it — the STEP trials are the most-cited semaglutide data in existence — but the funding source belongs in every story. Most coverage left it out or buried it.

What Mainstream Media Is Getting Wrong

Reporters are conflating the retatrutide story and the semaglutide-in-seniors story into one blob of "weight loss drug news" without distinguishing what's actually new.

The NYT headline — "Experimental Drug Yields Dramatic Weight Loss" — is accurate but generic. 28% average loss at 80 weeks is a clinical benchmark that no approved drug has hit.

Fox News covered a mouse study about an experimental drug "outperforming traditional GLP-1s" — useful context for the pipeline, but early-stage animal research gets conflated with human trial data when readers skim headlines. That's irresponsible framing regardless of which outlet does it.

The semaglutide-in-seniors finding barely registered in American outlets. A 15% average weight loss in a population that typically loses less with ANY intervention is genuinely significant — and it has direct implications for Medicare drug coverage policy, which is currently being fought over in Congress.

What This Means for Real People

If you're under 65 and obese: Retatrutide is still experimental. It's NOT approved. It's NOT available. But if Phase 3 data holds, the drug Eli Lilly is building toward approval could outperform everything currently on the market by a meaningful margin.

If you're over 65 and your doctor has been reluctant to prescribe Wegovy or Ozempic: Push back with the new Busetto analysis. The hesitancy was reasonable when data was limited. The data is no longer limited.

If you're a taxpayer: These drugs cost $1,000+ per month. Medicare is being pressured to cover them broadly. A drug that delivers 28% average weight loss in 80 weeks might justify that cost better than one delivering 15% — but only if long-term maintenance data holds. We don't have that yet for retatrutide.